3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Sarcoma
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroblastoma
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Carcinoma, Bronchogenic
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Filgrastim
7
Carboplatin
5
Thiotepa
3
Temozolomide
3
Peripheral Blood Stem Cell Transplantation
3
Ifosfamide
3
sargramostim
2
motexafin gadolinium
2
etoposide phosphate
2
Sunitinib
2
Radiosurgery
2
Paclitaxel
2
Melphalan
2
Immunohistochemistry
2
Granulocyte Colony-Stimulating Factor
2
Gene Expression Profiling
2
Etoposide
2
Busulfan
2
Amplified Fragment Length Polymorphism Analysis
2
Amifostine
2
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
tanespimycin
1
pentetreotide
1
pembrolizumab
1
oblimersen
1
liposomal doxorubicin
1
ixabepilone
1
guadecitabine
1
gallium Ga 68 dotatate
1
erythromycin propionate-N-acetylcysteinate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Kidney Neoplasms
×
Interleukin-15
×
CNS
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled